"The investigators concluded that the incidence of CV events was lower in patients treated with sitagliptin compared with sulphonylureas. They cautioned that more research is warranted and they noted the effect of sitagliptin on CV outcomes currently is being evaluated prospectively in a randomised, placebo-controlled trial."